Test Price
2,800 AED✅ Home Collection Available
MRPS22 Gene Combined Oxidative Phosphorylation Deficiency Type 5 Genetic Test in UAE
Executive Summary & Core Metrics
Clinical Excellence & Patient-Centric Assurance
- ✓ 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified Genomic Sequencing with dual platform verification.
- ✓ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Complimentary service available daily from 8 AM to 11 PM across UAE, including Dubai, Abu Dhabi, Sharjah & Northern Emirates.
- ✓ Post-Test Telephonic Clinical Guidance – Dedicated molecular geneticist counsels on results interpretation and next steps.
- ✓ Instant Insurance Verification – WhatsApp +971 54 548 8731 for direct billing pre‑approval.
Test Overview & Methodology
This next‑generation sequencing test analyzes the entire coding region of the MRPS22 gene to detect pathogenic variants causing Combined Oxidative Phosphorylation Deficiency Type 5 (COXPD5), a rare mitochondrial disorder.
| Feature | Our Test (MRPS22‑NGS) | Closest Alternative (Broad Metabolic Panel) |
|---|---|---|
| Precision | Single‑gene resolution; 99.9% base‑calling accuracy | Multi‑analyte, non‑specific; may miss point mutations |
| Methodology | NGS (Illumina® platform, 150x mean depth) | Biochemical assays / multiplex PCR |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks (non‑genetic) |
| Interpretative Report | ACMG‑based, with carrier status & familial risk | Quantitative metabolites only |
Physician Insight & Safety Protocols
“This test is a critical piece of the diagnostic puzzle—it must always be correlated with clinical phenotype, family history, and functional studies. A negative result does not exclude mitochondrial disease; a positive result empowers early intervention and reproductive planning. Your care journey deserves the utmost empathy and precision.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠ Do not discontinue or adjust any prescribed medication prior to or during testing without explicit guidance from your treating physician.
Exclusion Criteria & Emergency Red Flags
- Unwillingness to provide informed genetic consent (mandatory under UAE medical liability regulations).
- Acute metabolic decompensation (severe lethargy, intractable vomiting, hypoglycaemia).
- Neurological deterioration: sudden loss of milestones, seizures, or altered consciousness.
- Haemodynamic instability requiring immediate emergency care.
If any red flag appears, seek emergency medical attention before proceeding with elective genetic testing.
Patient FAQs & Clinical Guidance
1. What is the MRPS22 gene test used for?
It identifies DNA variants in the MRPS22 gene to confirm a diagnosis of Combined Oxidative Phosphorylation Deficiency Type 5, a rare mitochondrial disorder. This test helps guide clinical management and family planning decisions.
2. How is the sample collected, and does it require fasting?
We collect a small whole blood sample (2–5 mL in EDTA tube) or DNA via FTA card. No fasting is necessary for this genetic test. Sample collection can be performed at your home by our trained mobile phlebotomist.
3. When will I receive my results, and what support is available?
Results are available in 3–4 weeks. You will receive a telephonic genetic counselling session with our Consultant Medical Geneticist to explain the findings and discuss implications.
UAE Regulatory & Data Privacy Adherence
Compliance with UAE Law
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with the highest confidentiality and security standards. Patient consent is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | MRPS22 Gene Combined Oxidative Phosphorylation Deficiency Type 5 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next-Generation Sequencing (Illumina®, 150x mean depth) |
| ICD-10-CM Code | E88.49 (Other mitochondrial metabolism disorders) |
| LOINC Code | 93935-3 (Mitochondrial genome sequencing) |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians